Role of drug disposition in drug hypersensitivity: A chemical, molecular, and clinical perspective

Chemical Research in Toxicology

Volumn 11, Issue 9, 1998, Pages 969-988

  Park, B Kevin ^a   Pirmohamed, Munir ^a   Kitteringham, Neil R ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMINOPHENAZONE; AMODIAQUINE; CAPTOPRIL; CEPHALOSPORIN; CEPHALOSPORIN DERIVATIVE; CLOZAPINE; COTRIMOXAZOLE; ENFLURANE; GOLD; HALOTHANE; LEVAMISOLE; METHOXYFLURANE; METHYLDOPA; NOMIFENSINE; PENICILLIN G; PHENYTOIN; PROPYLTHIOURACIL; PROTAMINE; QUINIDINE; STREPTOKINASE; SUXAMETHONIUM; THIOPENTAL; TRIMETHOPRIM; TUBOCURARINE CHLORIDE; UNINDEXED DRUG; VALPROIC ACID;

BLOOD DYSCRASIA; DRUG DISPOSITION; DRUG EFFECT; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG PROTEIN BINDING; HUMAN; LIVER TOXICITY; REVIEW; STEVENS JOHNSON SYNDROME;

BIOTRANSFORMATION; DRUG HYPERSENSITIVITY; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS;

EID: 0031719374     PISSN: 0893228X     EISSN: None     Source Type: Journal    
DOI: 10.1021/tx980058f     Document Type: Review

References (216)

1. Einarson, T. R. (1993) Drug-related hospital admissions. Ann. Pharmacother. 27, 832-840.
2. Bates, D. W., Cullen, D. J., Laird, N., Petersen, L. A., Small, S. D., Servi, D., Laffel, G., Sweitzer, B. J., Shea, B. F., Hallisey, R., Vandervliet, M.,Nemeskal, R., and Leape, L. L. (1995) Incidence of adverse drug events and potential adverse drug events: implications for prevention. J. Am. Med. Assoc. 274, 29-34.
3. Bates, D. W., Spell, N., Cullen, D. J., Burdick, E., Laird, N., Petersen, L. A., Small, S. D., Sweitzer, B. J., and Leape, L. L. (1997) The costs of adverse drug events in hospitalized patients. J. Am. Med. Assoc. 277, 307-311.
4. Park, B. K., Pirmohamed, M., and Kitteringham, N. R. (1992) Idiosyncratic drug reactions: a mechanistic evaluation of risk factors. Br. J. Clin. Pharmacol 34, 377-395.
5. Roitt, I., Brostoff, J., and Male, D. (1996) Immunology, 4th ed., Mosby, London.
6. Vitorrio, C. C., and Muglia, J. J. (1995) Anticonvulsant hypersensitivity syndrome. Arch. Intern. Med. 155, 2285-2290.
7. Pirmohamed, M., Breckenridge, A. M., Kittenngham N. R., and Park B. K. (1998) Adverse Drug Reactions: Current status. Br. Med. J. 316, 1295-1298.
8. Gell, P. G. H., and Coombs, R. R. A. (1963) Clinical aspects of immunology, Blackwell, Oxford, U.K.
9. Bour, H., Peyron, H., Gaucherand, M., Garrigue, J. L., Desvignes, C.,Kaiserlian, D., Revillard, J. P., and Nicolas, J. F.(1995) Major histocompatibility complex class I-restncted CD8+ T cells and class II-restricted CD4+ cells, respectively mediate and regulate contact sensitivity to dinitrofluorobenzene. Eur. J. Immunol. 25, 3006-3010.
10. Ahlstedt, S., Ekstrom, B., Svard, P. O., Sjoberg B., Kristofferson, A., and Ortengren, B. (1980) New aspects on antigens in penicillin allergy. CRC Crit. Rev. Toxicol 1, 219-277.
11. Park, B. K, Coleman, J. W., and Kitteringham, N. R. (1987) Drug disposition and drug hypersensitivity. Biochem. Pharmacol 36, 581-590.
12. Klaus G. G. B., and Humphrey, J. H. (1993) The fate of antigens. In Clinical aspects of immunology (Lachmann, P. J., Peters, D. K., Rosen, F. S., and Walport, M. J., Eds.) 5th ed., pp 107-126, Blackwell Scientific Publications, Oxford, U.K.
13. Landsteiner, K., and Jacobs, J. (1935) Studies on the sensitization of animals with simple chemical compounds. J. Exp. Med. 61, 643-656.
14. de Weck, A. L., and Eisen, H. N. (1960) Some immunological properties of penicillenic acid. An antigenic determinant derived from penicillin. J. Exp. Med. 112, 122-147.
15. Levine, B. B, and Ovary, Z. (1961) Studies on the mechanism of the formation of the penicillin antigen. J. Exp. Med. 114, 875- 1153.
16. Batchelor, F. R., Dewdney, J. M, and Gazzard, D. (1965) Penicillin allergy: the formation of the pemcilloyl determinant. Nature 206, 362-364.
17. Moulon, C., Vollmeer, J., and Weltzien, H.-U. (1995) Characterisation of processing requirements and metal cross-reactivities in T cell clones from patients with allergic contact dermatitis to nickel. Eur. J. Immunol. 25, 3308-3315.
18. Schnyder, B., Mauri-Hellweg, D., Zanni, M., Bettens, F., and Pichler, W. J. (1997) Direct MHC-dependent presentation of the drug sulfamethoxazole to human alpha beta T cell clones. J. Clin. Invest. 100, 136-141.
19. Gill, H. J., Hough, S. J., Naisbitt, D. J., Maggs, J. L., Kitteringham, N. R., Pirmohamed, M., and Park, B. K. (1997) The relationship between the disposition and immunogenicity of sulfamethoxazole in the rat. J. Pharmacol. Exp. Ther. 282, 795- 801.
20. Pirmohamed, M., and Park, B. K. (1996) Cytochromes P450 and Immunotoxicity. In Cytochromes P450: Metabolic and Toxicological Aspects (Ioannides, C., Ed.) PP 329-354, CRC Press, Boca Raton, FL.
21. Greim, P., Panthel, K., Kalbacher, H., and Gleichmann, E. (1996) Alteration of a model antigen by Au(III) leads to T cell sensitization to cryptic peptides. Eur. J. Immunol. 26, 279-287.
22. Christie, G., Coleman, J., and Park, B. K. (1988) Drug-Protein Conjugates XVII The effect of storage on the disposition and immunogenicity of benzylpenicillin in the rat. Biochem. Pharmacol 37, 4121-4128.
23. Park, B. K., and Kitteringham, N. R. (1990) Drug-protein conjugation and its immunological consequences. Drug Metab. Rev. 22, 87-144.
24. Park, B. K., Tingle, M. D., Grabowski, P. S., Coleman J. W., and Kitteringham, N. R. (1987) Drug-protein conjugates XI. Disposition and immunogenicity of dinitrofluorobenzene, a model compound for the investigation of drugs as haptens. Biochem. Pharmacol. 36, 591-599.
25. Furst, L. M., Luedke, D., Htoo-Htoo, G., Reich, R., and Gandolfi, A. J. (1997) Demonstration of a cellular immune response in halothane-exposed Guinea pigs. Toxicol. Appl. Pharmacol. 143, 245-255
26. Martin, S., and Weltzien, H. U. (1994) T cell recognition of haptens, a molecular view. Int. Arch. Allergy Immunol. 104, 10- 16.
27. Knight, C. G., and Green, N. M. (1979) Interaction of dinitrophenyl groups bound to bovine serum albumin with univalent fragments of anti-dinitrophenyl antibody. Biochem. J. 177, 225- 236.
28. Kalergis A. M., Lopez, C. B., Becker, M. I., Diaz, M. I., Sein, J., Garbarino, J. A., and De loannes, A. E. (1997) Modulation of fatty acid oxidation alters contact hypersensitivity to urushiols: Role of aliphatic beta-oxidation in processing and activation of urushiols. J. Invest. Dermatol. 108, 57-61.
29. Parker, C. W. (1982) Allergie reactions in man. Pharmacol. Rev. 34, 85-104.
30. Page, M. I. (1984) The mechanisms of reaction of beta-lactam antibiotics. Acc. Chem. Res. 17, 144-151.
31. Park, B. K., Pirmohamed, M., and Kitteringham, N. R. (1995) The role of cytochrome P450 enzymes in hepatic and extrahepatic human drug toxicity. Pharmacol. Ther. 68, 385-424.
32. Kharasch, E. D., Hankins, D., Mautz, D., and Thummel, K. E. (1996) Identification of the enzyme responsible for oxidative halothane metabolism: implications for prevention of halothane hepatitis. Lancet 347, 1367-1371.
33. Kenna, J. G., Satoh, H., Christ, D. D., and Pohl, L. R. (1988) Metabolic basis for a drug hypersensitivity: Antibodies in sera from patients with halothane hepatitis recognize liver neoantigens that contain the trifluoroacetyl group derived from halothane. J. Pharmacol. Exp. Ther. 245, 1103-1109.
34. Kitteringham, N. R., Kenna, J. G., and Park, B. K. (1995) Detection of autoantibodies directed against human hepatic endoplasmic-reticulum in sera from patients with halothane-associated hepatitis. Br. J. Clin. Pharmacol. 40, 379-386.
35. Bourdi, M., Chen, W., Peter, R. M., Martin, J. L., Buters, J. T., Nelson, S. D., and Pohl, L. R. (1996) Human cytochrome P450 2E1 is a major autoantigen associated with halothane hepatitis. Chem. Res. Toxicol. 9, 1159-1166.
36. Urban, G., Speerschneider, P., and Dekant, W. (1994) Metabolism of the chlorofluorocarbon substitute l, l-dichloro-2,2,2-trifluoro-ethane by rat and human liver microsomes: the role of cytochrome P450 2E1. Chem. Res. Toxicol. 7, 170-176.
37. Hoet, P., Graf, M. L. M., Bourdi, M., Pohl, L. R., Duray, P. H., Chen, W., Peter, R. M., Nelson, S. D., Verlinden, N., and Lison, D. (1997) Epidemie of liver disease caused by hydrochlorofluorocarbons used as ozone-sparing substitutes of chlorofluorocarbons. Lancet 350, 556-559.
38. Zimmerman, H. J., Lewis, J. H., Ishak, K. G., and Maddrey, W. C. (1984) Ticrynafen-associated hepatic injury: analysis of 340 cases. Hepatology 4, 315-323.
39. Beaune, P., Pessayre, D., Dansette, P., Mansuy, D., and Manns, M. (1994) Autoantibodies against cytochromes P450: Role in human diseases. Adv. Pharmacol. 30, 199-245.
40. Jean, P., Lopez-Garcia, P., Dansette, P., Mansuy, D., and Goldstein, J. L. (1996) Oxidation of tienilic acid by human yeast-expressed cytochromes P450, 2C8, 2C9, 2C18 and 2C19. Evidence that this drug is a mechanism-based inhibitor specific for cytochrome P450 2C9. Eur. J. Biochem. 241, 797-804.
41. Lecoeur, S., Andre, C., and Beaune, P. H. (1996) Tienilic acid-induced autoimmune hepatitis: Anti-liver and kidney microsomal type 2 autoantibodies recognise a three-site conformational epitope on cytochrome P4502C9. Mol. Pharmacol. 50, 326-333.
42. Robin, M. A., Maratrat, M., Le Roy, M., Le Breton, F. P., Bonierbale, E., Dansette, P., Ballet, F., Mansuy, D., and Pessayre, D. (1996) Antigenic targets in tienilic acid hepatitis. Both cytochrome P450 2C11 and 2C11-tieniIic acid adducts are transported to the plasma membrane of rat hepatocytes and recognised by human sera. J. Clin. Invest. 6, 1471-1480.
43. Uetrecht, J. P. (1996) Reactive metabolites and agranulocytosis. Eur. J. Haematol. 57, 83-88.
44. Uetrecht, J. P., Ma, H. M., MacKnight, E., and McClelland, R. (1995) Oxidation of aminopyrine by hypochlorite to a reactive dication: possible implications for amino-pyrine-induced agranu-locytosis. Chem. Res. Toxicol. 8, 226-233.
45. Tingle, M. D., Jewell, H., Maggs, J. L., O'Neill, P. M., and Park, B. K. (1995) The bioactivation of amodiaquine by human polymorphonuclear leucocytes in vitro: chemical mechanisms and the effects of fluorine substitution. Biochem. Pharmacol. 50, 1113- 1119.
46. Clarke, J. B., Maggs, J. L., Kitteringham, N. R., and Park, B. K. (1990) Immunogenicity of amodiaquine in the rat. Int. Arch. Allergy Appl. Immunol. 91, 335-342.
47. Clarke, J. B., Neftel, K., Kitteringham, N. R., and Park, B. K (1991) Detection of antidrug IgG antibodies in patients with adverse drug reactions to amodiaquine. Int. Arch. Allergy Appl. Immunol. 95, 369-375.
48. Ruscoe, J. E., Hough, S. J., Kitteringham, N. R., and Park, B. K. (1996) The investigation of an animal model for amodiaquine- induced agranulocytosis and hepatotoxicity. Hum. Exp. Toxicol. 15, 649.
49. Waldhauser, L., and Uetrecht, J. (1991) Oxidation of propylthiouracil to reactive metabolites by activate neutrophils. Drug Metab. Dispos. 19, 354-359.
50. Guffy, M. M., Gueken, N. E., and Burns, C. P. (1984) Granulocytotoxic antibodies in a patient with propylthiouracil-induced agranulocytosis. Arch. Intern. Med. 144, 1687-1688.
51. Fibbe, W. E., Claas, F. H. J., Van der Star-Dijlstra, W., Schaafsma, M. R., Meyboom, R. H. B., and Falkenberg, J. H. F. (1986) Agranulocytosis induced by propylthiouracil: evidence of a drug- dependent antibody reacting with granulocytes. Br. J. Haematol. 64, 363-373.
52. Toth, E. L., Mant, M. J., Shamim, S., and Ginsberg, J. (1988) Propylthiouracil-induced agranulocytosis: an unusual presentation and a possible mechanism. Am. J. Med. 85, 725-727.
53. Pirmohamed, M., and Park, B. K. (1997) Mechanism of action of clozapine-induced agranulocytosis: current status of research and implications for drug development. CNS Drugs 7, 139-158.
54. Williams, D. P., Pirmohamed, M., Naisbitt, D. J., Maggs, J. L., and Park, B. K. (1997) Neutrophil cytotoxicity of the chemically reactive metabolite(s) of clozapine: possible role in agranulocytosis. J. Pharmacol. Exp. Ther. 283, 1375-1382.
55. Spahn-Langguth, H., and Benet, L. Z. (1992) Acyl glucuronides revisited: Is the glucuronidation process a toxification as well as detoxification mechanism? Drug Metab. Rev. 24, 5-47.
56. Smith, P. C., McDonagh, A. F., and Benet, L. Z. (1986) Irreversible binding of zomepirac to plasma protein in vitro and in vivo. J. Clin. Invest. 77, 934-939.
57. Ojingwa, J. C., Spahn-Langguth, H., and Benet, L. Z. (1994) Reversible binding of tolmetin, zomepirac, and their glucuronide conjugates to human serum albumin and plasma. J. Pharma- cokinet. Biopharm. 22, 19-40.
58. Pumford, N. R., Myers, T. G., Davila, J. C., Highet, R. J., and Pohl, L. R. (1993) Immunochemical detection of liver protein adducts of the nonsteroidal antiinflammatory drug diclofenac. Chem. Res. Toxicol. 6, 147-150.
59. Kretz-Rommel, A., and Boelsterli, V. A. (1994) Mechanism of covalent adduct formation of diclofenac to rat hepatic microsomal proteins. Retention of the glucuronic acid moiety in the adduct. Drug Metab. Dispos. 22, 956-961.
60. Hargus, S. J., Amouzedeh, H. R., Pumford, N. R., Myers, T. G., McCoy, S. C., and Pohl, L. R. (1994) Metabolic activation and immunochemical localization of liver protein adducts of the nonsteroidal anti-inflammatory drug diclofenac. Chem. Res. Toxicol. 7, 575-582.
61. Miyamoto, G., Zahid, N., and Uetrecht, J. P. (1997) Oxidation of diclofenac to reactive intermediates by neutrophils, myeloperoxidase, and hypochlorous acid. Chem. Res. Toxicol. 10, 414-419.
62. Park, B. K., Pirmohamed, M., Tingle, M. D., Madden, S., and Kitteringham, N. R. (1994) Bioactivation and bioinactivation of drugs and drug metabolites: Relevance to adverse drug reactions. Toxicol. in Vitro 8, 613-621.
63. Buchmuller-Rouiller, Y., Corradin, S. B., Smith, J., Schneider, P., Ransijn, A., Jongeneel, V., and Mauel, J. (1995) Role of glutathione in macrophage activation: effect of cellular glutathione depletion on nitrite production and leishmanicidal activity. Cell. Immunol. 164, 73-80.
64. Shi, M. M., Kugelman, A., Iwamoto, T., Tian, L., and Forman, H. J. (1994) Quinone-induced oxidative stress elevates glutathione and induces gamma-glutamylcysteine synthetase activity in rat lung epithelial L2 cells. J. Biol. Chem. 269, 26512-26517.
65. Rechsteiner, M., Rogers, S., and Rote, K. (1987) Protein structure and intracellular stability. Trends Biochem. Sci. 12, 390-394.
66. Bohley, P. (1996) Surface hydrophobicity. Biol. Chem. Hoppe-Seyler 377, 425-435.
67. Grune, T., Reinheckel, T., and Davies, K. J. (1997) Degradation of oxidised proteins in mammalian cells. FASEB J. 11, 526-534.
68. Kalish, R. S. (1995) Antigen processing: The gateway to the immune response. Am. Acad. Dermatol. 32, 640-652.
69. Jardetzky, T. S., Lane, W. S., Robinson, R. A., Madden, D. R., and Wiley, D. C. (1991) Identification of self-peptides bound to purified HLA-B27. Nature 353, 326.
70. Weltzien, H. U., Moulon, C., Martin, S., Padovan, E., Hartmann, U., and Kohler, J. (1996) T cell immune responses to haptens. Structural models for allergic and autoimmune reactions. Toxicology 107, 141-151.
71. Leeder, J. S., Gaedigk, A., Lu, X., and Cook, V. A. (1996) Epitope mapping studies with human anti-cytochrome P450 3A antibodies. Mol. Pharmacol, 49, 234-243.
72. Basham, T. Y., Nickoloff, B. J., Merigan, T. C., and Morhenn, V. B. (1984) Recombinant gamma interferon includes HLA-DR expression on cultured human keratinocytes. J. Invest. Dermatol. 83, 88-90.
73. Pober, J. S., Gimbrone, M. A., Cotran, R. S., Reiss, C. S., Burakoff, J., Fiers, W., and Ault, K. A. (1983) Ia expression by vascular endothelium is inducible by activated T cells and by human gamma interferon. J. Exp. Med. 157, 1339-1353.
74. Yang, Y., Walters, J. B., Fruh, K., and Peterson, P. A. (1992) Proteasomea are regulated by interferon gamma: Implications for antigen processing. Proc. Natl. Acad. Sci. U.S.A. 89, 4928- 4932.
75. Germain, R. N. (1994) MHC-dependent antigen processing and peptide presentation: providing ligands for T lymphocyte activation. Cell 76, 287-299.
76. Matzinger, P. (1994) Tolerance, danger, and the extended family. Annu. Rev. Immunol. 12, 991-1045.
77. Lafaye, P., and Lapresle, C. (1988) Fixation of penicilloyl groups to albumin and appearance of anti-penicilloyl antibodies in penicillin-treated patients. J. Clin. Invest. 82, 7-12.
78. Romagnoli, P., Labhardt, A. M., and Sinigaglia, F. (1991) Selective interaction of Ni with an MHC-bound peptide. EMBO J. 10, 1303-1308.
79. Romagnoli, P., Spinas, G. A., and Sinigaglia, F. (1992) Gold-specific T cells in rheumatoid arthritis patients treated with gold. J. Clin. Invest. 89, 254-258.
80. Sinigaglia, F. (1994) The molecular basis of metal recognition by T cells. J. Invest. Dermatol. 102, 398-401.
81. Reiser, H., and Stadecker, M. J. (1996) Costimulatory B7 molecules in the pathogenesis of infectious and autoimmune diseases. Mech. Dis. 335, 1369-1377.
82. Guinan, E. C., Gribben, J. G., Boussiotis, V. A., Freeman, G. J., and Nadler, L. M. (1994) Pivotal role of the B7-CD28 pathway in transplantation tolerance and tumour immunity. Blood 84, 3261- 3282.
83. Bluestone, J. A. (1995) New perspectives of CD28-B7 mediated T cell costimulation. Immunology 2, 555-559.
84. Harding, F. A., and Allison, J. P. (1993) CD28-B7 interactions allow the induction of CD8+ cytotoxic T lymphocytes in the absence of exogenous help. J. Exp. Med. 177, 1791-1796.
85. Dearman, R. J., Mitchell, J. A., Basketter, D. A., and Kimber, I. (1992) Differential ability of occupational chemical contact and respiratory allergens to cause immediate and delayed dermal hypersensitivity reactions in mice. Int. Arch. Allergy Immunol. 97, 315-321.
86. Dearman, R. J., Basketter, D. A., and Kimber, I. (1995) Differential cytokine production following chronic exposure of mice to chemical respiratory and contact allergens. Immunology 86, 545-550.
87. Rook, G. A. W., and Zumla, A. (1997) Gulf War syndrome: is it due to a systemic shift in cytokine balance towards a Th2 profile? Lancet 349, 1831-1832.
88. van der Meide, P. H., de Labie, M. C. D. C., Botman, C. A. D., van Bennekom, W. P., Olsson, T., Aten, J., and Weening, J. J. (1993) Mercuric chloride down-regulates T cell interferon-γ production in Brown Norway but not in Lewis rats; role of glutathione. Eur. J. Immunol. 23, 675-681.
89. Le Gros, G., Ben-Sasson, S. Z., Seder, R., Finkelman, F. D., and Paul, W. E. (1990) Generation of interleukin 4(IL-4)-producing cells in vivo and in vitro: IL-2 and IL-4 are required for in vitro generation of IL-4-producing cells. J. Exp. Med. 172, 921-929.
90. Rhodes, J., Chen, H., Hall, S. R., Beesley, J. E., Jenkins, D. C., Collins, P., and Zheng, B. (1995) Therapeutic potentiation of the immune system by costimulatory Schiff-base forming drugs. Nature 377, 71-75.
91. Shearer, G. M. (1995) Redirecting T-cell function. Nature 377, 16-17.
92. Furst, S. M., and Uetrecht, J. P. (1993) Carbamazepine metabolism to a reactive intermediate by the myeloperoxidase system of activated neutrophils. Biochem. Pharmacol. 45, 1267-1275.
93. Pirmohamed, M., Madden, S., and Park, B. K. (1996) Idiosyncratic drug reactions: metabolic bioactivation as a pathogenic mechanism. Clin. Pharmacokinet. 31, 215-230.
94. van der Klauw, M. M., Stricker, B. H., Herings, R. M., Cost, W. S., Valenburg, H. A., and Wilson, J. H. (1993) A population based case-cohort study of drug-induced anaphylaxis. Br. J. Clin. Pharmacol. 35, 400-408.
95. Baldo, B. A., and Fisher, M. M. (1983) Detection of serum IgE antibodies that react with alcuronium and tubocurarine after life-threatening reactions to muscle-relaxant drugs. Anaesth. Intensive Care 11, 194-197.
96. Zhu, D. X., Zhao, J. L., Mo, L., and Li, H. L. (1997) Drug allergy: Identification and characterization of IgE-reactivities to aspirin and related compounds. J. Invest. Allergol. Clin. Immunol. 7, 160-168.
97. Pham, N. H., and Baldo, B. A. (1996) Beta-lactam drug allergens: Fine structural recognition patterns of cephalosporin- reactive IgE antibodies. J. Mol. Recognit. 9, 287-296.
98. Christie, G., Coleman, J. W., Newby, S., McDiarmid-Gordon, J. P., Hampson, J. P., Breckenridge, A. M., and Park, B. K. (1988) A study of the prevalence of penicillin-specific IgG, IgM and IgE antibodies detected by ELISA and defined by hapten inhibition, in patients with suspected penicillin allergy and in healthy volunteers. Br. J. Clin. Pharmacol. 25, 381-386.
99. Sanz, M. L., Garcia, B. E., Prieto, I., Tabar, A., and Oehling, A. (1996) Specific IgE determination in the diagnosis of beta-lactam allergy. J. Invest. Allergol. Clin. Immunol. 6, 89-93.
100. Baldo, B. A., Pham, N. H., and Weiner, J. (1995) Detection and side-chain specificity of IgE antibodies to flucloxacillin in allergic subjects. J. Mol. Recognit. 8, 171-177.
101. Weiss, M. E., Nyhan, D., Peng, Z. K., Horrow, J. C., Lowenstein, E., Hirshman, C., and Adkinson, N. F. (1989) Association of protamine IgE and IgG antibodies with life-threatening reactions to intravenous protamine. N. Engl. J. Med. 320, 886-892.
102. Tisdale, J. E., Stringer, K. A., Antalek, M., and Matthews, G. E. (1989) Streptokinase-induced anaphylaxis. Drugs Curr. Pract. 23, 984-987.
103. Harle, D. G., Baldo, B. A., and Wells, J. V. (1988) Drugs as allergens: detection and combining site specificities of IgE antibodies to sulfamethoxazole. Mol. Immunol. 25, 1347-1354.
104. Gruchalla, R. S., and Sullivan, T. J. (1991) Detection of human IgE to sulfamethoxazole by skin testing with sulfamethoxazoyl- poly-L-tyrosine. J. Allergy Clin. Immunol. 88, 784-792.
105. Harle, D. G., Baldo, B. A., and Fisher, M. M. (1984) Detection of IgE antibodies to suxamethonium after anaphylactoid reactions during anaesthesia. Lancet i, 930-932.
106. Harle, D. G., Baldo, B. A., Smal, M. A., Wajon, P., and Fisher, M. M. (1986) Detection of thiopentone-reactive IgE antibodies following anaphylactoid reactions during anesthesia. Clin. Allergy 16, 493-498.
107. Harle, D. G., Baldo, B. A., and Fisher, M. M. (1990) The molecular basis of IgE antibody-binding to thiopentone: binding of IgE from thiopentone-allergic and nonallergic subjects. Mol. Immunol. 27, 853-858.
108. Harle, D. G., Baldo, B. A., Smal, M. A., and Vannunen, S. A. (1987) An immunoassay for the detection of IgE antibodies to trimethoprim in the sera of allergic patients. Clin. Allergy 17, 209-216.
109. Pham, N. H., Baldo, B. A., Manfredi, M., and Zerboni, R. (1996) Fine-structural specificity differences of trimethoprim allergenic determinants. Clin. Exp. Allergy 26, 1155-1160.
110. van der Klauw, M. M., Wilson, J. H., and Stricker, B. H. (1996) Drug-associated anaphylaxis: 20 years of reporting in the Netherlands (1974-1994) and review of the literature. Clin. Exp. Allergy 26, 1355-1363.
111. Kemp, S. F., Lockey, R. F., Wolf, B. L., and Lieberman, P. (1995) Anaphylaxis: a review of 266 cases. Arch. Intern. Med. 155, 1749-1754.
112. Brander, C., Mauri-Hellweg, D., Bettens, F., Rolli, H., Goldman, M., and Pichler, W. J. (1995) Heterogeneous T-cell responses to beta-lactam-modified self-structure s are observed in penicillin- allergic individuals. J. Immunol., 2670-2678.
113. Weiss, M. E., and Adkinson, M. F. (1988) Immediate hypersensitivity reactions to penicillin and related antibiotics. Clin. Allergy 18, 515-540.
114. Casolaro, V., Georas, S. N., Song, Z., and Ono, S. J. (1996) Biology and genetics of atopic disease. Curr. Opin. Immunol. 8, 796- 803.
115. Sladek, K., and Szczeklik, A. (1993) Cysteinyl leukotrienes overproduction and mast cell activation in aspirin-provoked bronchospasm in asthma. Eur. Respir. J. 6, 391-399.
116. O'Sullivan, S., Dahlen, S. E., and Kumlin, M. (1996) Increased urinary excretion of the prostaglandin D2 metabolite 9α,11βprostaglandin F2 after aspirin challenge supports mast cell activation in aspirin-induced airway obstruction. J. Allergy Clin. Immunol. 98, 421-432.
117. Zhu, D., Becker, W. M., Schulz, K. H., Schubeler, K., and Schlaak, M. (1992) The presence of specific IgE to salicyloyl and O-methylsalicyloyl in aspirin-sensitive patients. Asia Pac. J. Allrgy Immunol. 10, 25-32.
118. Orlan, N., Patterson, R., and Dykewicz, M. S. (1990) Severe angiooedema related to ACE inhibitors in patients with a history of idiopathic angioedema. J. Am. Med, Assoc. 264, 1287-1289.
119. Lang, D. M. (1995) Anaphylactoid and anaphylactic reactions. Hazards of beta-blockers. Drug Saf. 12, 299-304.
120. Paton, W. (1957) Histamine release by compounds of simple chemical structure. Pharmacol. Rev. 9, 269-301.
121. Youngman, P. R., Taylor, K. M., and Wilson, J. D. (1983) Anaphylactoid reactions to neuromuscular blocking agents: a commonly undiagnosed condition. Lancet ii, 597-599.
122. Didier, A., Cador, D., Bongrand, P., Furstoss, R., Fourneron, P., Senft, M., Philip-Joet, F., Charpin, D., Charpin, J., and Vervloet, D. (1987) Role of the quaternary ammonium ion determinants in allergy to muscle relaxants. J. Allergy Clin. Immunol. 79 , 578-584.
123. Finch, R. G. (1993) The withdrawal of temafloxacin. Are there implications for other quinolones? Drug Saf. 8, 9-11.
124. Habibi, B. (1987) Drug-induced immune haemolytic anaemias. Bailliere's Clin. Immunol. Allergy 1, 343-355.
125. Mueller-Eckhardt, C. (1987) Drug-induced immune thrombocytopenia. Bailliere's Clin. Immunol. Allergy 1, 369-389.
126. Claas, F. H. J. (1987) Drug-induced immune granulocytopenia. Bailliere's Clin. Immunol. Allergy 1, 357-367.
127. Petz, L. D., and Fundenberg, H. H. (1966) Coombs-positive hemolytic anemia caused by penicillin administration. N. Engl. J. Med. 274, 171-178.
128. Levine, B., and Redmond, A. (1967) Immunochemical mechanisms of penicillin induced Coombs positivity and hemolytic anemia in man. Int. Arch. Allergy Appl. Immunol. 21, 594-606.
129. Habibi, B. (1987) Drug-induced immune haemolytic anaemias. Bailliere's Clin. Immunol. Allergy 1, 343-355.
130. Gralnick, H. R., McGinniss, M., Elton, W., and McCurdy, P. (1971) Hemolytic anemia associated with cephalosporin. J. Am. Med. Assoc., 1193-1197.
131. Chambers, L. A., Donovan, L. M., and Kruskall, M. S. (1990) Ceftazidime-induced hemolysis in a patient with drug-dependent antibodies reactive by immune complex and drug adsorption mechanisms. Am. J. Clin. Pathol. 95, 393-396.
132. Shulman, I. A., Arndt, P. A., McGehee, W., and Garratty, G. (1990) Cefotaxime-induced immune hemolytic anemia due to antibodies reacting in vitro by more than one mechanism. Transfusion 30, 263-266.
133. Garraty, G. (1991) Severe immune haemolytic anaemia associated with newer cephalosporins. Lancet 338, 119-120.
134. Bernini, J. C., Mustafa, M. M., Sutor, L. J., and Buchanan, G. R. (1995) Fatal hemolysis induced by ceftriaxone in a child with sickle cell anemia. J. Pediatr. (St. Louis) 126, 813-815.
135. Salama, A., and Mueller-Eckhardt, C. (1985) The role of metabolite-specific antibodies in nomifensine-dependent immune haemolytic anaemia. N. Engl. J. Med. 313, 469-474.
136. Ammus, S., and Yunis, A. A. (1989) Drug-induced red cell dyscrasias. Blood Rev. 3, 71-82.
137. Uetrecht, J. P. (1992) The role of leukocyte-generated reactive metabolites in the pathogenesis of idiosyncratic drug reactions. Drug Metab. Rev. 24, 299-366.
138. Madison, F. W., and Squier, T. L. (1934) The etiology of primary granulocytopenia (agranulocytic angina). J. Am. Med. Assoc. 102, 755-759.
139. Dameshek, W., and Colmes, A. (1935) The effect of drugs in the production of agranulocytosis with particular reference to amidopyrine hypersensitivity. J. Clin. Invest. 15, 85-97.
140. Goudemand, J., Plouvier, J., Bauters, F., and Goudemand, M. (1976) Acute agranulocytosis induced by pyramidon or phenothiazines. Apropos of 31 cases. Sem. Hop. 52, 1513-1520.
141. Barrett, A. J., Weller, E., Rozengurt, N., Longhurst, P., and Humble, J. G. (1976) Aminopyrine agranulocytosis: drug inhibition of granulocyte colonies in the presence of patient's serum. Br. Med. J. 2, 850-851.
142. Moeschlin, S., and Wagner, K. (1952) Agranulocytosis due to the occurrence of leucocyte-agglutinins. Acta Haematol. 8, 29-41.
143. Magis, C. C., Barge, A., and Dausset, J. (1968) Serological study of an allergic agranulocytosis due to noraminopyrine. Clin. Exp. Immunol. 3, 989-1003.
144. Barrett, A. J., Weller, E., Rozengurt, N., Longhurst, P., and Humble, J. G. (1976) Aminopyrine agranulocytosis: drug inhibition of granulocyte colonies in the presence of patient's serum. Br. Med. J. 2, 850-851.
145. Uetrecht, J. P. (1992) The role of leukocyte-generated reactive metabolites in the pathogenesis of idiosyncratic drug reactions. Drug Metab. Rev. 24, 299-366.
146. Savill, J. S., Wyllie, A. M., Henson, J. E., Walport, M. J., Henson, P. M., and Haslett, C. (1989) Macrophage phagocytosis of aging neutrophils in inflammation: programmed cell death in the neutrophil leads to its recognition by macrophages. J. Clin. Invest. 83, 865-873.
147. Watson, R. W. G., Redmond, H. P., Wang, J. H., and Bouchier- Hayes, D. (1995) Human neutrophil apoptosis is induced by an oxygen-dependent mechanism. Br. J. Surg. 82, 703-704.
148. Bigby, M., Jick, S., and Arndt, K. (1986) Drug-induced cutaneous reactions: a report from the Boston Collaborative Drug Surveillance Program on 15, 438 consecutive inpatients, 1975-1982. J. Am. Med. Assoc. 256, 3358-3363.
149. Pirmohamed, M., Kitteringham, N. R., and Park, B. K. (1994) The role of active metabolites in drug toxicity. Drug Saf. 11, 114-144.
150. Roujeau, J. C., and Stern, R. S. (1994) Severe adverse cutaneous reactions to drugs. N. Engl. J. Med. 331, 1273-1285.
151. Stingl, G., Gazze-Stingl, L. A., Aberer, W., and Wolff, K. (1981) Antigen presentation by murine epidermal Langerhans cells and its alteration by ultraviolet B light. J. Immunol. 127, 2005- 2013.
152. Kripke, M. L., Munn, C. W., Jeevan, A., Tang, J.-M., and Bucana, C. (1990) Evidence that cutaneous antigen-presenting cells migrate to regional lymph nodes during contact sensitization. J. Immunol. 145, 2833.
153. Roujeau, J.-C., Kelly, J. P., Naldi, L., Razny, B., Stern, R. S., Anderson, T., Auquier, A., Bastuji-Garin, S., Correia, O., Locati, F., Mockenhaupt, M., Paoletti, C., Shapiro, S., Shear, N., Schopf, E., and Kaufman, D. W. (1995) Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N. Engl. J. Med. 333, 1600-1607.
154. Shear, N. H., Spielberg, S. P., Cannon, M., and Miller, M. (1988) Anticonvulsant hypersensitivity syndrome: in vitro risk assessment. J. Clin. Invest. 82, 1826-1832.
155. Pirmohamed, M., Graham, A., Roberts, P., Smith, D., Chadwick, D., Breckenridge, A. M., and Park, B. K. (1991) Carbamazepine hypersensitivity: assessment of clinical and in vitro chemical cross-reactivity with phenytoin and oxcarbazepine. Br. J. Clin. Pharmacol. 32, 741-749.
156. Wadelius, M., Karlsson, T., Wadelius, C., and Rane, A. (1996) Lamotrigine and toxic epidermal necrolysis. Lancet 348, 1041.
157. Miyauchi, H., Hosokawa, H., Akaeda, T., Iba, H., and Asada, Y. (1991) T-cell subsets in drug-induced toxic epidermal necrolysis. Possible pathogenic mechanism induced by CD8-positive T cells. Arch. Dermatol. 127, 851-855.
158. Villada, G., Roujeau, J.-C., Clerici, T., Bourgault, I., and Revuz, J. (1992) Immunopathology of toxic epidermal necrolysis. Arch. Dermatol. 128, 50-53.
159. Correia, O., Delgado, L., Ramos, J. P., Resende, C., and Torrinha, J. A. F. (1993) Cutaneous T-cell recruitment in toxic epidermal necrolysis. Arch. Dermatol. 129, 466-468.
160. Friedmann, P. S., Strickland, I., Pirmohamed, M., and Park, B. (1994) Investigation of mechanisms in toxic epidermal necrolysis induced by carbamazepine. Arch. Dermatol. 130, 598-604.
161. Carr, A., Vasak, E., Munro, V., Penny, R., and Cooper, D. A. (1994) Immunohistological assessment of cutaneous drug hypersensitivity in patients with HIV infection. Clin. Exp. Immunol. 97, 260-265.
162. Smith, K. J., Skelton, H. G., Yeager, J., Ledsky, R., Ng, T. H., and Wagner, K. F. (1997) Increased drug reactions in HIV-1- positive patients: a possible explanation based on patterns of immune dysregulation seen in HIV-1 disease. Clin. Exp. Der- matol. 22, 118-123.
163. Pessayre, D. (1995) Role of reactive metabolites in drug-induced hepatitis. J. Hepatol. 23, 16-24.
164. Boelsterli, U. A., Zimmerman, H. J., and Kretz-Rommel, A. (1995) Idiosyncratic liver toxicity of nonsteroidal antiinflamma- tory drugs: Molecular mechanisms and pathology. Crit. Rev. Toxicol. 25, 207-235.
165. National Halothane Study (1966) Summary of the national halothane study. J. Am. Med. Assoc. 197, 121-134.
166. Zimmerman, H. J. (1978) Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver, Appleton-Century Crofts, New York.
167. Colliard, M., Homberg, J. C., and Tcherdakoff, P. (1981) Hyper- tensive patients treated with tielinic acid. A retrospective study of 298 cases. Nouv. Presse Med. 10, 2475-2478.
168. Dunk, A. A., Walt, R. P., Jenkins, W. J., and Sherlock, S. S. (1982) Diclofenac hepatitis. Br. Med. J. 284, 1605-1606.
169. Bren, E. G., McNicholl, J., Cosgrove, E., McCabe, J., and Stevens, F. M. (1986) Fatal hepatitis associated with diclofenac. Gut 27, 1390-1393.
170. Kretz-Rommel, A., and Boelsterli, U. A. (1995) Cytotoxic activity of T cells and non-T cells from diclofenac-immunized mice against cultured syngeneic hepatocytes exposed to diclofenac. Hepatology 22, 213-222.
171. Scully, L, J., Clarke, D., and Barr, R. J. (1993) Diclofenac induced hepatitis: three cases with features of autoimmune chronic active hepatitis. Dig. Dis. Sci. 38, 744-751.
172. Banks, A. T., Zimmerman, H. J., Ishak, K. G., and Harter, J. G. (1995) Diclofenac-associated hepatotoxicity: analysis of 180 cases reported to the Food and Drug Administration as adverse reactions. Hepatology 22, 820-827.
173. Kappler, J. W., Roehmn, N., and Marrack, P. (1987) T-cell tolerance by clonal elimination in the thymus. Cell 9, 273-280.
174. Joshua, D., Liu, Y., Williams, G., Smith, C., Gordon, J., and MacLennan, I. (1996) Mechanism of antigen-driven selection in germinal centres. Nature 342, 929-931.
175. Fakhro, A. M., Ritchie, R. F., and Lown, B. (1967) Lupus-like syndrome induced by procainamide. Am. J. Cardiol. 20, 367- 373.
176. Hope, R. R., and Bates, L. A. (1972) The frequency of procainamide-induced systemic lupus erythematosus. Med. J. Aust. 2, 298-303.
177. Bluestein, H. G., Zvaifler, N. J., Weisman, M. H., and Shapiro, R. F. (1979) Lymphocyte alteration by procainamide: relation to drug-induced lupus erythematosus syndrome. Lancet 2, 816- 819.
178. Lee, S. L., and Chase, P. H. (1975) Drug-induced systemic lupus erythematosus: a critical review. Semin. Arthritis Rheum. 5, 83-103.
179. Dubois, E. L., Molina, J., Bilitch, M., and Friou, G. J. (1968) Procainamide-induced serological changes in asymptomatic patients. Arthritis Rheum. 11, 477-481.
180. Alarcon-Segovia, D. (1969) Drug-induced lupus syndromes. Mayo Clin. Proc. 44, 664-681.
181. Perry, H. M., Jr., Tan, E. M., Carmody, S., and Sakamoto, A. (1970) Relationship of acetyl transferase activity to antinuclear antibodies and toxic symptoms in hypertensive patients treated with hydralazine. J. Lab. Clin. Med. 76, 114-125.
182. Cameron, H. A., and Ramsay, L. E. (1984) The lupus syndrome induced by hydralazine: a common complication with low dose treatment. Br. Med. J. 289, 410-412.
183. Bourdi, M., Larrey, D., Nataf, J., Bernuau, J., Pessayre, D., Iwasaki, M., Guengerich, F. P., and Beaune, P. (1990) Anti-liver endoplasmic reticulum autoantibodies are directed against human cytochrome P450IA2, a specific marker of dihydralazine- induced hepatitis. J. Clin. Invest. 85, 1967 -1973.
184. Beaune, P. H., and Bourdi, M. (1993) Autoantibodies against cytochrome P-450 in drug-induced autoimmune hepatitis. Ann. N.Y. Acad. Sci. 685, 641-645.
185. Leeder, J. S., Riley, R. J., Cook, V. A., and Spielberg, S. P. (1992) Human anti-cytochrome P450 antibodies in aromatic anticon-vulsant-induced hypersensitivity reactions. J. Pharmacol. Exp. Ther. 263, 360-367.
186. Meyers, D. A., Bias, W. B., and Marsh, D. G. (1982) A genetic study of total IgE levels in the Amish. Hum. Hered. 32, 15-23.
187. Hershey, G. K. K., Freidrich, M. F., Esswein, L. A., Thomas, M. L., and Chatila, T. A. (1997) The association of atopy with a gain-of-function mutation in the alpha-subunit of the interleukin-4 receptor. N. Engl. J. Med. 337, 1720-1725.
188. Park, J. S., Choi, I. H., Lee, D. G., Han, S. S., Ha, T. Y., Lee, J. H., Lee, W. H., Park, Y. M., and Lee, H. K. (1997) Anti-IL-4 monoclonal antibody prevents antibiotics-induced active fatal anaphylaxis. J. Immunol. 158, 5002-5006.
189. Berson, A., Freneaux, E., Larrey, D., Lepage, V., Douay, C., Mallet, C., Fromenty, B., Benhamou, J.-P., and Pessayre, D. (1994) Possible role of HLA in hepatotoxicity. J. Hepatol. 20, 336-342.
190. Pirmohamed, M., and Park, B. K. (1995) Drug reactions in HIV infected patients. Postgrad. Doctor 18, 438-444.
191. Ott, M., Emiliani, S., Van Lint, C., Herbein, G., Lovett, J., Chirmule, N., McCloskey, T., Pahwa, S., and Verdin, E. (1997) Immune hyperactivation of HIV-1-infected T cells mediated by Tat and the CD28 pathway. Science 275, 1481-1485.
192. Zack, J. A., Arrigo, S. J., Weitstein, S. R., Go, A. S., Haislip, A., and Chen, I. S. Y. (1990) HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell 61, 213-222.
193. Stevenson, M., Stanwick, T. L., Dempsey, M. P., and Lamonica, C. A. (1990) HIV-1 replication is controlled at the level of T cell activation and proviral integration. EMBO J. 9, 1551-1560.
194. Pantaleo, G., and Fauci, A. S. (1995) New concepts in the immunopathogenesis of HIV infection. Annu. Rev. Immunol. 13, 487-512.
195. Baier-Bitterlich, G., Fuchs, D., and Wachter, H. (1997) Chronic immune stimulation, oxidative stress, and apoptosis in HIV infection. Biochem. Pharmacol. 53, 755-763.
196. Huber, C., Batchelor, J. R., Fuchs, D., Hausen, A., Lang, A., Niederwieser, D., Reibnegger, G., Swetly, P., Troppmair, J., and Wachter, H. (1984) Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-gamma. J. Exp. Med. 160, 310-316.
197. Bitterlich, G., Szabo, G., Werner, E. R., Larcher, C., Fuchs, D., Hausen, A., Reibnegger, G., Schulz, T. F., Troppmair, J., and Wachter, H. (1988) Selective induction of mononuclear phagocytes to produce neopterin by interferons. Immunobiology 176, 228-235.
198. Greene, W. (1990) Regulation of HIV-1 gene expression. Annu. Rev. Immunol. 8, 453-475.
199. Veenstra, J., Veuggelers, P. J., Keet, I. P. M., van der Ven, A. J. A. M., Miedema, F., Lange, J. M. A., and Coutinho, R. A. (1997) Rapid disease progression in human immunodieficiency virus type 1-infected individuals with adverse drug reactions to trimethoprim-sulphamethoxazole prophylaxis. Clin. Infect. Dis. 24, 936-941.
200. de-Quay, B., Malinverni, R., and Lauterburg, B. H. (1992) Glutathione depletion in HIV-infected patients: role of cysteine deficiency and effect of oral N-acetylcysteine. AIDS (London) 6, 815-819.
201. Roederer, M., Staal, F. J. T., Osada, H., Herzenberg, L. A., and Herzenberg, L. A. (1991) CD4 and CD8 T cells with high intracellular glutathione levels are selectively lost as the HIV infection progresses. Int. Immunol. 3, 933-937.
202. Buhl, R., Holroyd, K. J., Mastrangeli, A., Cantin, A. M., Jaffe, H. A., Wells, F. B., Saltini, C., and Crystal, R. G. (1989) Systemic glutathione deficiency in symptom-free HIV-seropositive individuals. Lancet 2, 1294-1298.
203. Eck, H.-P., Gmunder, H., Hartmann, M., Petzoldt, D., Daniel, V., and Droge, W. (1989) Low concentrations of acid-soluble thiol (cysteine) in the plasma of HIV-1 infected patients. Biol. Chem. Hoppe-Seyler 370, 101-108.
204. Pirmohamed, M., Williams, D., Tingle, M. D, Barry, M., Khoo, S. H., O'Mahony, C., Wilkins, E. G. L., Breckenridge, A. M., and Park, B. K. (1996) Intracellular glutathione in the peripheral blood cells of HIV-infected patients: failure to show a deficiency. AIDS (London) 10, 501-507.
205. Aukrust, P., Svardal, A. M., Muller, F., Lunden, B., Berge, R. K., Ueland P. M., and Froland, S. S. (1995) Increased levels of oxidized glutathione in CD4+ lymphocytes associated with disturbed intracellular redox balance in human immunodeficiency virus type 1 infection. Blood 86, 258-267.
206. Walmsley, S. L., Winn, L. M., Harrison, M. L., Uetrecht, J. P., and Wells, P. G. (1997) Oxidative stress and thiol depletion in plasma and peripheral blood lymphocytes from HIV-infected patients: toxicological and pathological implications. AIDS (London) 11, 1689-1697.
207. Osborne, B. A. (1996) Apoptosis and maintenance of hoemeostasis in the immune system. Curr. Opin. Immunol. 8, 245- 254.
208. Metcalf, D. (1997) Another way to generate T cells? Nat. Med. 3, 18-19.
209. Lind, R. C., and Gandolfi, A. J. (1989) The role of oxidative biotransformation of halothane in the Guinea pig model of halothane-associated hepatotoxicity. Anesthesiology 70, 878- 884.
210. Coleman, J. W., Foster, A. L., Yeung, J. H. K., and Park, B. K. (1988) Drug-protein conjugates XV. A study of the disposition of D-penicillamine in the rat and its relationship to immunogenicity. Biochem. Pharmacol. 37, 737-742.
211. 14C]captopril to plasma proteins in the rat. Biochem. Pharmacol. 31, 1755-1760.
212. Park, B. K., and Kitteringham, N. R. (1994) Effects of fluorine substitution on drug-metabolism: pharmacological and toxicological implications. Drug Metab. Rev. 26, 605-643.
213. Matzinger, P. (1994) Memories are made of this? Immunology 369, 605-606.
214. Mazze, R. I., Trudell, J. R., and Cousins, M. J. (1971) Methoxyflurane metabolism and renal disfunction. Anesthesiology 35, 247-252.
215. Weitz, J., Kienle, P., Bohrer, H., Hofmann, W., Theilmann, L., and Otto, G. (1997) Fatal hepatic necrosis after isoflurane anaesthesia. Anaesthesia 52, 892-895.
216. Njoku, D., Laster, M. J., Gong, D. H., Eger, E. I., II, Reed, G. F., and Martin, J. L. (1997) Biotransformation of halothane, enflurane, isoflurane, and desflurane to trifluoroacetylated liver proteins: association between protein acylation and hepatic injury. Anesth. Analg. (N.Y.) 84, 173-178.